InspireMD Inc

InspireMD, Inc. is a medical device company focused on developing and commercializing products to treat carotid artery disease and other vascular conditions. It operates in the United States, Germany, Italy, Russia, Poland, and internationally. Its offerings include MicroNet, a biocompatible polymer mesh material for medical implants and for treating plaque prolapse and embolization; the CGuard carotid embolic prevention system (EPS); the CGuard Prime Carotid Stent System; and the SwitchGuard neuroprotection system, which provides flow reversal for cerebral protection in carotid interventions and treats acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.

NSPR▼

InspireMD Q2 2026 Earnings Call: Recall Impact and Regulatory Timeline

InspireMD reported flat second-quarter revenue due to the voluntary recall of its CGuard Prime 135 system, which required $734,000 in customer credits that offset underlying U.S. sales growth. International business grew 21% year-over-year, and the company implemented a 20% workforce reduction to align costs with near-term regulatory priorities. Management anticipates potential FDA approval for both the CGuard Prime 80 and the original CGuard CAS platform in the fourth quarter of 2026, with the redesigned CGuard Prime 135 delivery system targeted for a first-half 2027 market reentry. The recall resulted in a $612,000 impairment charge and a restructuring charge between $900,000 and $1.2 million is expected in the third quarter of 2026. Cash and equivalents decreased to $30.4 million as of June 30, 2026, down from $54.2 million at year-end 2025.

NSPR ▼

Yahoo Finance·32dRead more →